VistaGen Therapeutics Inc (VTGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.01M
Last updated: Nov 17, 2026 at 11:04 AM ET
VistaGen Therapeutics Inc (VTGN) Competitors
The companies most similar to VistaGen Therapeutics are Biovie (BIVI), Tempest Therapeutics (TPST) and Theriva Biologics (TOVX). By market cap, VistaGen Therapeutics ranks 5th of the 13 companies on this page; Passage Bio (PASG) is the largest at $13.68M.
Peer Comparison
VTGN's revenue growth of -46.5% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| VistaGen Therapeutics (VTGN) | $8.01M | N/A | 3.4x | 0.0% | N/A | -46.5% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Soligenix Inc. (SNGX) | $7.50M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Ensysce Biosciences Inc (ENSC) | $8.14M | N/A | 1.2x | -280.5% | -260.6% | -15.1% | 0.00% |
| Vyome Holdings, Inc. (HIND) | $11.09M | N/A | N/A | 0.0% | N/A | 67.5% | 0.00% |
| Reviva Pharmaceuticals Holdings Inc. (RVPH) | $4.63M | N/A | N/A | 0.0% | -90.2% | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $5.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Passage Bio Inc (PASG) | $13.68M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Exicure Inc (XCUR) | $7.07M | N/A | N/A | 0.0% | N/A | 928.0% | 0.00% |
| Peer median | $7.57M | N/A | 11.4x | 0.0% | -175.4% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to VistaGen Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Soligenix Inc. (SNGX) | Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. | SNGX competitors |
| Ensysce Biosciences Inc (ENSC) | Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. | ENSC competitors |
| Vyome Holdings, Inc. (HIND) | Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States... | HIND competitors |
| Reviva Pharmaceuticals Holdings Inc. (RVPH) | Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for central nervous... | RVPH competitors |
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapies for renal diseases and associated... | CVKD competitors |
| Passage Bio Inc (PASG) | Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. | PASG competitors |
| Exicure Inc (XCUR) | Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases... | XCUR competitors |
Frequently Asked Questions About VTGN
Who are VistaGen Therapeutics' main competitors?
The companies most similar to VistaGen Therapeutics include Biovie (BIVI), Tempest Therapeutics (TPST), Theriva Biologics (TOVX), GT Biopharma (GTBP) and Soligenix (SNGX), listed from the closest match.
Who is VistaGen Therapeutics' biggest competitor?
Passage Bio (PASG) is the largest of the similar companies at $13.68M; Biovie (BIVI) is the closest match by business profile, size, sector and industry.
How does VTGN stock compare with its competitors?
VTGN's P/S is 3.4x against a peer median of 11.4x; its net margin is 0.0% against a peer median of 0.0%.
Which of VistaGen Therapeutics' competitors pays a higher dividend?
VistaGen Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is VistaGen Therapeutics bigger than its competitors?
No. VistaGen Therapeutics is 5th by market cap among the 13 companies on this page; the largest is Passage Bio (PASG) at $13.68M.
VTGN pages: Overview, Earnings, Forecast, Financials, Competitors